{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"46.7","value":"27889"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"title":"Cycle 1, Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"42.7","value":"263131"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"48"}],"units":"Participants"}],"title":"Cycle 2, Day 1"}],"denoms":[{"counts":[{"groupId":"OG000","value":"58"}],"units":"Participants"}],"description":"Plasma enasidenib was measured using validated liquid chromatography-mass spectrometry methods (LC-MS/MS). The lower limit of quantification (LLOQ) in plasma was 1.00 ng/mL. Area under the plasma concentration-time curve from time 0 to 24 hours post-dose (AUC0-24) was calculated using the linear trapezoidal rule.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants received enasidenib 100 mg QD on Day 1 to Day 28 of each 28-day treatment cycle until disease progression or development of unacceptable toxicity.","id":"OG000","title":"Phase 2: Enasidenib 100 mg QD"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"Participants who received enasidenib on Cycle 1 Day 1 or Cycle 2 Day 1 with sufficient data to determine PK parameters. Participants who took less than 80% of their planned continuous dosing regimen were excluded from the analysis of Cycle 2 Day 1.","reportingStatus":"POSTED","timeFrame":"Cycle 1 Day 1 and Cycle 2 Day 1 at predose and 2, 4, 6, 8, and 24 hours post-dose.","title":"Phase 2: Area Under the Plasma Concentration Time Curve From Time Zero to 24 Hours Postdose (AUC 0-24) of Enasidenib After Single and Multiple Oral Doses","type":"SECONDARY","unitOfMeasure":"ng*h/mL"}